Fig. 1: Gemcitabine response in NSCLC cells with TP53 mutations. | Cell Death Discovery

Fig. 1: Gemcitabine response in NSCLC cells with TP53 mutations.

From: Utilizing TP53 hotspot mutations as effective predictors of gemcitabine treatment outcome in non-small-cell lung cancer

Fig. 1

A The Cancer Genome Atlas (TCGA) database highlights TP53 as one of the most frequently mutated genes in adenocarcinoma of non-small cell lung cancer (NSCLC). B Data extracted from the Cancer Genome Atlas (TCGA) database reveals the mutation frequency of TP53 in NSCLC adenocarcinoma. TP53 mutations encompass 55% of cases, including 40.7% missense mutations, 11% truncating mutations, and 3.3% splice mutations. C A scatter plot illustrates the half-maximal inhibitory concentration (IC50) values for gemcitabine treatment in NSCLC adenocarcinoma cell lines categorized as TP53 wild-type (WT), harboring hotspot mutations, or non-hotspot mutant. The data suggests potential variations in gemcitabine sensitivity based on TP53 mutational status.

Back to article page